CJC/Ipamorelin

Scientific Overview

CJC/Ipamorelin is a two-peptide research stack: the short-acting CJC GHRH analog (not CJC-1295 with Drug Affinity Complex) plus ipamorelin, a selective growth-hormone secretagogue. Each component has its own literature. This page does not claim a single pivotal trial of the fixed combination.

Mechanism focus

CJC-class peptides are studied at the GHRH receptor. Ipamorelin is studied as a ghrelin-receptor agonist with selective GH release in preclinical work. Combination use is a research design that engages both pathways.

Research Use Cases

• Combined GHRH-receptor and ghrelin-receptor models
• Growth-hormone axis co-stimulation studies
• Comparison with either component alone
• Identity testing of two-peptide preparations

Use-Case Study Notations

• Case-study notation: ipamorelin papers describe a selective growth-hormone secretagogue, separate from GHRH analogs.
• Case-study notation: CJC-1295 pharmacokinetic trials describe the DAC analog and are not studies of this stack.
• Read the CJC and Ipamorelin pages for the single-compound identities.

Selected Studies

1. 01 Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH releasing hormone analogPubMed 16352683
2. 02 Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, enhances GH and IGF-I secretionPubMed 16822960
3. 03 Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changesPubMed 19386527
4. 04 Ipamorelin, the first selective growth hormone secretagoguePubMed 9849822
5. 05 Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileusPubMed 19289567

Related compounds

CJC · Ipamorelin